TherapeuticsMD (NASDAQ:TXMD) Stock, Quote.Headers.trade-ideas

TherapeuticsMD

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

I53 Investments Since 2017

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

AULT

TXMD

TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying

Small Cap

Pre-Market Outlook

Movers

ADTN

AIMD

ALNA

ANTX

APGN

ATXG

AVCO

AVTX

AVYA

BBBY

BIAF

BIVI

BLTE

BRCN

CAMP

CMCM

CRTD

CTMX

CYTK

DRMA

DWAC

ECOM

EHTH

EIGR

Sunrise New Energy Co., Ltd - Ordinary Shares

EPOW

EURN

FAZE

FRZA

FUTU

FWBI

GEHI

GETY

GROV

GRTX

HIVE

HLVX

HPCO

HYRE

IDAI

ISEE

MGAM

MLTX

MNMD

NEON

NUTX

NUWE

ONVO

PIXY

PROK

PXMD

RGLS

RGTI

SERA

SHPH

SLQT

SPRO

SQFT

TELL

TNGX

WHLR

WING

WTRH

ZETA

ZFOX

ZYME

Gainers


	Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH) shares jumped 91.3% to close at $28.50 on Tuesday amid post-IPO volatility.


Why Allena Pharmaceuticals Tumbled Over 30%; Here Are 85 Biggest Movers From Yesterday

Intraday Update

AMTD

GILD

ILMN

MEGL

POSH

SNAP

TLRY

VRDN


	Magic Empire Global Limited (NASDAQ: MEGL) shares climbed 80.9% to $14.87 on volatility following the company&#39;s IPO earlier this month.


Snap, Gilead Sciences And Some Other Big Stocks Moving Higher On Monday

TherapeuticsMD Inc

TherapeuticsMD (TXMD) has provided an announcement. TherapeuticsMD, Inc., a healthcare company, announced its annual financial results for 2023 on ...

TherapeuticsMD Announces 2023 Annual Financial Results

TherapeuticsMD Inc (TXMD) stock is down -36.66% over the last 12 months. InvestorsObserver's proprietary ranking system, gives TXMD stock a score of  10 out of a possible 100. That rank is mainly influenced by a short-term technical score of 15. TXMD's rank also includes a long-term technical score of 16.  TXMD has an Over

TherapeuticsMD Inc (TXMD) Stock  Gains 2.62% This Week: Is It a Good Pick?

Therapeutics MD GAAP EPS of -$0.07

TherapeuticsMD (TXMD) has provided an announcement. TherapeuticsMD, Inc., a Nevada-based company, has released its financial results for the first ...

TherapeuticsMD Releases Preliminary Q1 2024 Financials

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TherapeuticsMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txmd-stock-quote/"><strong>TXMD</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>TherapeuticsMD reported earnings per share of -7 cents.</li><li>The company reported revenue of $313,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/txmd-stock-earnings-therapeuticsmd-for-q1-of-2024/">TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024

Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TherapeuticsMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txmd-stock-quote/"><strong>TXMD</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>TherapeuticsMD reported earnings per share of -14 cents.</li><li>The company reported revenue of $502,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/txmd-stock-earnings-therapeuticsmd-for-q4-of-2023/">TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

TXMD Stock Earnings: TherapeuticsMD Reported Results for Q4 2023

TherapeuticsMD (TXMD) has shared an update. TherapeuticsMD, Inc. recently disclosed its financial outcomes for the quarter ending June 30, 2024, th...

TherapeuticsMD Releases Preliminary Quarterly Financial Results

Therapeutics MD GAAP EPS of -$0.09

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>TherapeuticsMD</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/txmd-stock-quote/"><strong>TXMD</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>TherapeuticsMD reported earnings per share of -9 cents.</li><li>The company reported revenue of $234,000.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/txmd-stock-earnings-therapeuticsmd-for-q2-of-2024/">TXMD Stock Earnings: TherapeuticsMD Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

TherapeuticsMD

TherapeuticsMD (TXMD) Forecast

TherapeuticsMD (NASDAQ:TXMD) Stock, Quote.Headers.trade-ideas